During a live event, Alfred L. Garfall, MD, discussed the dose adjustments and supportive care for toxicities seen with ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...

Darzalex as monotherapy was investigated in two main studies involving multiple myeloma patients whose disease relapsed after, or was refractory to, at least two previous treatments, including a ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

Signs and Symptoms That Occur With Multiple Myeloma As cancerous plasma cells multiply within the bone marrow, they reveal their presence in a number of ways. The main three tend to be: Bone Pain ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. The guidance recommends the ...

Breakthrough Trispecific Antibody Shows Strong Early Efficacy: JNJ-5322 demonstrated an 86.1% overall response rate (ORR) at the recommended Phase II dose in heavily pretreated multiple myeloma ...

Myeloma articles from across Nature Portfolio Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 ...

The future of multiple myeloma treatment is personalised, but collaboration is essential to deliver it. Learn about the latest advancements and how working together can improve outcomes for patients.

Both BMY’s Pomalyst and Revlimid are approved for multiple myeloma. Sanofi is also evaluating a fixed-dose subcutaneous (“SC”) formulation of Sarclisa for the treatment of R/R MM.